000 | 01713 a2200493 4500 | ||
---|---|---|---|
005 | 20250518073908.0 | ||
264 | 0 | _c20200102 | |
008 | 202001s 0 0 eng d | ||
022 | _a1178-2048 | ||
024 | 7 |
_a10.2147/VHRM.S226009 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aAlem, Manal M | |
245 | 0 | 0 |
_aEffect of Long-Term Allopurinol Therapy on Left Ventricular Mass Index in Patients with Ischemic Heart Disease; A Cross-Sectional Study. _h[electronic resource] |
260 |
_bVascular health and risk management _c2019 |
||
300 |
_a539-550 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Observational Study | ||
650 | 0 | 4 | _aAged |
650 | 0 | 4 | _aAged, 80 and over |
650 | 0 | 4 |
_aAllopurinol _xadverse effects |
650 | 0 | 4 |
_aAntioxidants _xadverse effects |
650 | 0 | 4 |
_aBiomarkers _xblood |
650 | 0 | 4 |
_aBlood Glucose _xdrug effects |
650 | 0 | 4 | _aCase-Control Studies |
650 | 0 | 4 |
_aCreatinine _xblood |
650 | 0 | 4 | _aCross-Sectional Studies |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 |
_aGlycated Hemoglobin _xmetabolism |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aHypertrophy, Left Ventricular _xblood |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 |
_aMyocardial Ischemia _xblood |
650 | 0 | 4 | _aTime Factors |
650 | 0 | 4 | _aTreatment Outcome |
650 | 0 | 4 |
_aVentricular Function, Left _xdrug effects |
650 | 0 | 4 |
_aVentricular Remodeling _xdrug effects |
700 | 1 | _aAldosari, Sarah R | |
700 | 1 | _aAlkahmous, Alhassna A | |
700 | 1 | _aObad, Adam S | |
700 | 1 | _aFagir, Nagy M | |
700 | 1 | _aAl-Ghamdi, Bandar S | |
773 | 0 |
_tVascular health and risk management _gvol. 15 _gp. 539-550 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.2147/VHRM.S226009 _zAvailable from publisher's website |
999 |
_c30411001 _d30411001 |